Advised by MAS Capital, Suntec Medical Plans for a US$100M Nasdaq IPO in 2027

TAIPEI, Taiwan--(BUSINESS WIRE)--Suntec Medical, Inc. retained MAS Capital (CI) Inc. as its exclusive IPO advisor for a US$100 million Nasdaq IPO in Q2 2027. Advised by MAS Capital, Suntec is under discussion with VCs for a US$25 million Series A private placement, which the Company expects to complete in Q3 2026. Suntec is seeking funding to expedite the clinical trials of its four drug candidates. Earlier this month MAS Capital proposed to make a strategic investment in Suntec. According to Ms. Rebecca Shih, strategic advisor to Suntec, “We believe with MAS Capital’s professional investment banking experience and capabilities, Suntec will successfully achieve its financial and clinical trial goals in a timely manner!”

Suntec has patented a revolutionary MINC Technology to develop new multi-target immunotherapies able to penetrate BBB (blood-brain barrier) into the brain to treat challenging CNS (central nervous system) diseases with high efficacy, high response rate and low toxicity. Suntec has developed four breakthrough, First-in-class and Best-in-class new therapies for Alzheimer’s & Parkinson’s diseases, Stroke/TBI (Traumatic Brain Injuries) and Brain Cancers. Due to the outstanding performances and superb safety of Suntec’s drugs, US FDA has granted short preclinical and clinical development process with future “Breakthrough Designation” potential. NIH has awarded MINC as “one of the most promising nanotechnology companies” with a 3-year support to facilitate its preclinical development. From NIH data, it showed the clinical trial success rates of MINC drugs will be very high.

“Suntec’s MINC technology is one of the most innovative new drug development platforms to generate complex drug molecules. MINC technology is superior to ADC and bi-, tri- specific antibody complex drug technologies to achieve high efficacy and clinical success rate. With the recent Nasdaq IPO of complex drugs, e.g. the Bicara Therapeutics’s bi-specific-antibody (dual-action EGFR/TGF-β) completed a $362 million IPO in September 2024, Suntec’s MINC new drugs, with tri/quad- actions (e.g. EGFR/PDGFR/IGF-1R/HER2 by STM-001) with superior efficacies in eight solid tumors, is expected to generate much higher enthusiasm in 2027 Nasdaq IPO,” said Aaron Tsai, Founder and Chief Capitalist of MAS Capital.

About Suntec Medical

Formed in California in 2005, Suntec, with prior funding by NIH, is a biotech company developing a pipeline of new drugs with a preclinical research facility in Taiwan, clinical research and business development teams in the US and EU and cooperation with renowned clinical researchers globally for the development of new drugs.

About MAS Capital

Since 1995 MAS Capital provides financial advisory services, direct investments and incubations to deep tech companies in North America and Greater China. MAS Capital’s advisory services include pre-IPO capital raise, Nasdaq and HKEX IPO, post-IPO capital raise, M&A and global expansion strategy. MAS Capital is a US investment bank with its Asian affiliate HQ based in Shanghai.